Pubertal Regulation of Bone-Endocrine Signaling: Mechanisms, Clinical Implications, and Emerging Insights

Abstract

Puberty is a critical period for skeletal development, governed by intricate hormonal interactions that regulate bone growth, remodeling, and mineralization. This review provides an in-depth examination of the endocrine mechanisms underlying pubertal modulation of bone physiology, emphasizing recent clinical and experimental findings. We synthesize epidemiological data, pathophysiological insights, and guideline-backed management approaches, focusing on clinically relevant aspects for healthcare professionals. Advances in our understanding of pubertal bone-endocrine signaling have significant implications for diagnosing and managing pediatric bone disorders, optimizing peak bone mass, and preventing future osteopathies.

Introduction

Bone health during adolescence is fundamentally shaped by the hormonal milieu of puberty. The transition from childhood to adulthood marks a period of accelerated linear growth and skeletal maturation, orchestrated by the interplay of growth hormone (GH), insulin-like growth factor-1 (IGF-1), sex steroids, parathyroid hormone (PTH), and other endocrine mediators. Disruptions in these regulatory pathways can predispose individuals to osteoporosis, fractures, and metabolic bone diseases later in life. Understanding the mechanistic basis and clinical implications of pubertal bone-endocrine signaling is essential for both preventive and therapeutic strategies in pediatric care.

Epidemiology / Disease Burden

Globally, approximately 90% of peak bone mass is accrued by the end of adolescence, with puberty contributing the largest increment. Epidemiological studies indicate that suboptimal bone mineralization during this period increases the lifetime risk of fractures and osteoporosis. Disorders of pubertal timing, such as precocious or delayed puberty, may adversely influence bone accrual. Clinical registries and cohort studies document higher rates of bone fragility and metabolic bone disease in populations with endocrine disturbances affecting pubertal progression, emphasizing the public health significance of this developmental window.

Pathophysiology

Pubertal bone growth is driven by the synergistic actions of GH-IGF-1 axis stimulation, sex steroid secretion (primarily estrogen and testosterone), and local factors such as fibroblast growth factors (FGFs) and bone morphogenetic proteins (BMPs). Estrogen, in particular, acts via both direct and indirect mechanisms: it promotes epiphyseal closure, enhances osteoblastic bone formation, and inhibits bone resorption by modulating osteoclast activity. Androgens stimulate periosteal apposition, contributing to gender differences in bone geometry and strength. Disruption of these pathways due to genetic, nutritional, or environmental factors can impair bone accrual and increase long-term fracture risk.

Risk Factors

Risk factors for impaired pubertal bone-endocrine signaling include chronic illnesses (e.g., inflammatory bowel disease, cystic fibrosis), malnutrition, eating disorders, physical inactivity, and exposure to endocrine-disrupting chemicals. Genetic syndromes affecting hormone receptors or signaling proteins (e.g., aromatase deficiency, androgen insensitivity) may also disrupt normal pubertal progression and skeletal development. Early or delayed onset of puberty alters the duration and magnitude of bone mineralization, compounding these risks.

Clinical Features

Clinically, aberrant bone-endocrine signaling during puberty may manifest as delayed or stunted growth, reduced bone mineral density (BMD), increased susceptibility to fractures, and altered skeletal proportions. In extreme cases, patients may present with overt metabolic bone disease, such as rickets or osteomalacia. Subtle signs, including delayed secondary sexual characteristics and impaired linear growth velocity, warrant further endocrine evaluation to exclude underlying hormonal dysregulation.

Diagnosis

Diagnosis relies on a combination of clinical assessment, auxological measurements, and laboratory investigations. Bone age determination via radiography, serum markers of bone turnover (e.g., osteocalcin, bone-specific alkaline phosphatase), and hormonal profiling (FSH, LH, estradiol, testosterone, IGF-1) are integral. Dual-energy X-ray absorptiometry (DXA) remains the gold standard for quantifying BMD. Genetic testing may be indicated in cases of suspected syndromic or familial bone-endocrine disorders.

Treatment & Management

Management strategies focus on optimizing pubertal timing and maximizing peak bone mass. Endocrine disorders are addressed with targeted hormone replacement (e.g., estrogen or testosterone for hypogonadism, GH therapy for growth hormone deficiency). Nutritional optimization, including adequate calcium and vitamin D intake, is essential. Physical activity, particularly weight-bearing exercise, is strongly recommended to stimulate bone formation. In select cases, antiresorptive agents or anabolic therapies may be considered under specialist guidance.

Recent Advances / Emerging Therapies

Recent research has elucidated the role of novel bone-derived hormones, such as osteocalcin and sclerostin, in mediating the crosstalk between bone and other endocrine organs during puberty. The Wnt/β-catenin pathway, targeted by agents like romosozumab, represents a promising therapeutic avenue for enhancing bone formation. Selective estrogen receptor modulators (SERMs) and aromatase inhibitors are under investigation for their potential to modulate pubertal bone accrual in specific clinical scenarios. Advances in genetic and molecular diagnostics permit earlier detection and personalized management of pubertal bone-endocrine disorders.

Guideline Recommendations

Professional societies, including the Endocrine Society and the International Society for Clinical Densitometry, recommend routine monitoring of bone health in adolescents with risk factors for endocrine or metabolic bone disease. Timely intervention for pubertal disorders, tailored hormone therapy, and lifestyle modifications form the cornerstone of evidence-based care. Emerging consensus guidelines advocate for multidisciplinary management, integrating pediatric endocrinology, nutrition, and orthopedic expertise to optimize outcomes.

Conclusion

The regulation of bone growth and mineralization during puberty is orchestrated by complex endocrine networks with profound clinical implications. Early identification and management of disruptions in pubertal bone-endocrine signaling are critical for ensuring optimal skeletal health and preventing future osteopathies. Ongoing research into bone-derived hormones and molecular pathways promises to refine diagnostic and therapeutic approaches, heralding a new era of personalized bone health strategies for adolescents.